LL-37: Antimicrobial Peptide Research and Wound Healing Mechanisms (UK 2026)

LL-37 is the only known human cathelicidin antimicrobial peptide, making it a uniquely significant research compound in immunology, microbiology, and wound healing science. It bridges the gap between innate immunity and tissue repair — directly killing pathogens while simultaneously promoting the wound healing cascade. This dual function has made LL-37 an increasingly prominent subject of research as antibiotic resistance concerns intensify and the need for novel antimicrobial and wound healing strategies grows.

Structure and Endogenous Origin

LL-37 is a 37-amino-acid cationic peptide derived from proteolytic cleavage of the C-terminal domain of the hCAP18 precursor protein (human cationic antimicrobial protein 18), encoded by the CAMP gene. Its name reflects its structure: it begins with two leucines (LL) and contains 37 amino acids total.

LL-37 is produced by neutrophils, monocytes, mast cells, T cells, NK cells, and epithelial cells of the skin, respiratory tract, gastrointestinal tract, and urogenital tract. This broad cellular distribution reflects its role as a front-line component of the innate immune system — produced rapidly at sites of infection or injury, before the adaptive immune response develops.

Expression is upregulated by bacterial products (lipopolysaccharide, lipoteichoic acid), vitamin D3 signalling through the vitamin D receptor (VDR), physical wounding, and inflammatory cytokines. This upregulation pattern positions LL-37 as a sensor and responder to tissue breach events.

Antimicrobial Mechanisms

LL-37’s antimicrobial activity operates through membrane disruption — its cationic (positively charged) amphipathic helix structure allows it to insert into the negatively charged membranes of bacteria, disrupting membrane integrity through a carpet, toroidal pore, or barrel-stave model. This physical disruption mechanism is fundamentally different from conventional antibiotics that target specific bacterial enzymes or biosynthetic pathways — making resistance development considerably more difficult.

Antibacterial spectrum: LL-37 demonstrates activity against both Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis) and Gram-negative bacteria (Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Helicobacter pylori). Of particular research interest is its activity against MRSA and other multidrug-resistant strains, where its membrane-disruptive mechanism retains efficacy.

Antifungal activity: LL-37 shows activity against Candida albicans and other fungal pathogens through similar membrane disruption mechanisms.

Antiviral activity: Research has demonstrated LL-37 activity against enveloped viruses including influenza A, herpes simplex virus, respiratory syncytial virus, and HIV-1. The mechanism involves disruption of the viral envelope and, for some viruses, direct interaction with nucleic acid.

Anti-biofilm properties: LL-37 disrupts bacterial biofilm formation — a major clinical challenge in wound infections and device-related infections. It both prevents biofilm establishment and degrades established biofilms through disruption of the extracellular matrix.

Wound Healing Mechanisms

Beyond direct antimicrobial activity, LL-37 plays important roles in all three major phases of wound healing:

Inflammatory phase: LL-37 acts as a chemoattractant for neutrophils, monocytes, and mast cells through formyl peptide receptor 2 (FPR2/FPRL1) and CXCR2 activation. This inflammatory cell recruitment is essential for pathogen clearance at the wound site. Simultaneously, LL-37 modulates the magnitude of the inflammatory response — preventing excessive inflammation that would impair healing through EGF receptor transactivation and LPS-neutralising activity.

Proliferative phase: LL-37 promotes keratinocyte migration and proliferation — the process of re-epithelialisation that closes the wound surface. It activates EGF receptor (EGFR) signalling in keratinocytes, driving the cell migration that underlies wound closure. It also promotes angiogenesis through FPRL1-mediated VEGF induction, increasing vascular supply to the healing wound.

Remodelling phase: LL-37 influences macrophage polarisation toward the pro-healing M2 phenotype, reducing chronic inflammatory signalling and promoting tissue remodelling. It modulates MMP (matrix metalloproteinase) activity, which is required for extracellular matrix remodelling during the maturation of healed tissue.

LL-37 in Chronic Wound Research

Chronic wounds — diabetic ulcers, venous leg ulcers, pressure injuries — are characterised by persistent inflammation, impaired angiogenesis, and reduced antimicrobial defence. LL-37 expression is markedly reduced in chronic wounds compared to acute wounds, suggesting that LL-37 deficiency may be mechanistically involved in the failure of normal healing.

Research into exogenous LL-37 application in chronic wound models has demonstrated: accelerated wound closure, improved granulation tissue formation, reduced bacterial burden, and enhanced re-epithelialisation. These findings have motivated clinical research interest in LL-37 as a therapeutic candidate for chronic wound indications — several early clinical trials have explored topical application.

Skin Condition Research

LL-37 expression is dysregulated in several skin conditions relevant to UK dermatology research:

Rosacea: Elevated LL-37 cleavage products (particularly a 37-amino-acid fragment processed differently by kallikrein-5) contribute to the vascular and inflammatory features of rosacea. Understanding this dysregulated processing pathway is active research.

Psoriasis: LL-37 forms complexes with self-DNA released from damaged keratinocytes, activating plasmacytoid dendritic cells via TLR9 — a mechanism contributing to the autoimmune amplification loop in psoriasis. Research into LL-37/DNA complex formation is relevant to psoriasis pathogenesis.

Atopic dermatitis: LL-37 expression is reduced in atopic dermatitis lesional skin, contributing to increased susceptibility to skin infections — particularly Staphylococcus aureus colonisation, which is near-universal in severe atopic disease.

Antibiotic Resistance Research Context

The emergence of multidrug-resistant organisms (MDROs) — MRSA, VRE, ESBL-producing Enterobacteriaceae, carbapenem-resistant Pseudomonas — represents one of the most significant challenges in modern microbiology. LL-37’s membrane disruption mechanism, combined with multiple secondary mechanisms (LPS neutralisation, immunomodulation), makes it scientifically interesting as a template for novel antimicrobial development.

Several research programmes are exploring LL-37 analogues with improved stability, lower toxicity, and enhanced antimicrobial potency. Understanding structure-activity relationships in LL-37 — which portions of the peptide are required for antimicrobial versus wound healing activity — is an active area of medicinal chemistry research.

UK Research Applications

UK research groups studying LL-37 span multiple disciplines: wound healing centres examining chronic wound pathophysiology; microbiology groups studying innate immunity and antibiotic resistance; dermatology units examining its role in skin barrier function; and pharmacology groups developing optimised analogues. COA-verified LL-37 from UK suppliers supports this research base.

Summary

LL-37 is one of the most multifunctional research peptides currently studied — uniquely combining broad-spectrum antimicrobial activity (bacterial, fungal, viral), wound healing promotion across all three phases of repair, and immunomodulatory properties. Its relevance to antibiotic resistance research, chronic wound pathophysiology, and skin barrier science makes it a compound of growing research interest in UK biomedical science.